- Home
- RIGL vs CHPT Comparison
RIGL vs CHPT Comparison
Compare RIGL & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- CHPT
- Stock Information
- Founded
- RIGL 1996
- CHPT 2007
- Country
- RIGL United States
- CHPT United States
- Employees
- RIGL N/A
- CHPT N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- RIGL Health Care
- CHPT Consumer Discretionary
- Exchange
- RIGL Nasdaq
- CHPT Nasdaq
- Market Cap
- RIGL 335.5M
- CHPT 340.1M
- IPO Year
- RIGL 2000
- CHPT N/A
- Fundamental
- Price
- RIGL $38.85
- CHPT $11.29
- Analyst Decision
- RIGL Buy
- CHPT Hold
- Analyst Count
- RIGL 5
- CHPT 10
- Target Price
- RIGL $38.20
- CHPT $29.13
- AVG Volume (30 Days)
- RIGL 995.6K
- CHPT 532.9K
- Earning Date
- RIGL 08-05-2025
- CHPT 09-03-2025
- Dividend Yield
- RIGL N/A
- CHPT N/A
- EPS Growth
- RIGL N/A
- CHPT N/A
- EPS
- RIGL 5.43
- CHPT N/A
- Revenue
- RIGL $267,921,000.00
- CHPT $407,681,000.00
- Revenue This Year
- RIGL $59.93
- CHPT $2.79
- Revenue Next Year
- RIGL N/A
- CHPT $24.20
- P/E Ratio
- RIGL $7.15
- CHPT N/A
- Revenue Growth
- RIGL 105.62
- CHPT N/A
- 52 Week Low
- RIGL $12.66
- CHPT $8.55
- 52 Week High
- RIGL $43.72
- CHPT $39.20
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- CHPT 47.09
- Support Level
- RIGL $39.00
- CHPT $11.41
- Resistance Level
- RIGL $42.08
- CHPT $11.85
- Average True Range (ATR)
- RIGL 2.32
- CHPT 0.59
- MACD
- RIGL -0.37
- CHPT 0.08
- Stochastic Oscillator
- RIGL 53.26
- CHPT 39.55
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.